Deutsche Bank AG Raises Stake in Heska Co. (NASDAQ:HSKA)

Deutsche Bank AG boosted its holdings in Heska Co. (NASDAQ:HSKA) by 8.0% during the second quarter, Holdings Channel.com reports. The fund owned 9,515 shares of the medical research company’s stock after buying an additional 708 shares during the quarter. Deutsche Bank AG’s holdings in Heska were worth $2,185,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in HSKA. Allianz Asset Management GmbH increased its stake in Heska by 144.5% in the 1st quarter. Allianz Asset Management GmbH now owns 156,149 shares of the medical research company’s stock worth $26,305,000 after acquiring an additional 92,285 shares during the last quarter. G2 Investment Partners Management LLC increased its stake in Heska by 83.4% in the 1st quarter. G2 Investment Partners Management LLC now owns 120,000 shares of the medical research company’s stock worth $20,215,000 after acquiring an additional 54,566 shares during the last quarter. Renaissance Technologies LLC increased its stake in Heska by 1,034.9% in the 1st quarter. Renaissance Technologies LLC now owns 48,800 shares of the medical research company’s stock worth $8,221,000 after acquiring an additional 44,500 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Heska by 605.4% during the 1st quarter. JPMorgan Chase & Co. now owns 46,747 shares of the medical research company’s stock valued at $7,875,000 after purchasing an additional 40,120 shares during the last quarter. Finally, Pinz Capital Management LP bought a new position in shares of Heska during the 1st quarter valued at about $5,033,000. Institutional investors and hedge funds own 94.92% of the company’s stock.

Several equities analysts have recently commented on HSKA shares. Piper Sandler increased their price objective on Heska from $240.00 to $305.00 and gave the company an “overweight” rating in a research report on Wednesday, August 4th. Guggenheim upgraded Heska from a “neutral” rating to a “buy” rating and set a $280.00 price objective on the stock in a research report on Monday, July 12th. Zacks Investment Research lowered Heska from a “buy” rating to a “hold” rating in a research report on Wednesday, October 6th. Finally, Alliance Global Partners reiterated a “buy” rating and set a $310.00 price objective (up from $240.00) on shares of Heska in a research report on Wednesday, August 4th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $268.00.

Shares of HSKA stock opened at $252.77 on Thursday. The stock has a market capitalization of $2.69 billion, a PE ratio of -1,330.37 and a beta of 1.72. Heska Co. has a 1-year low of $103.00 and a 1-year high of $275.94. The business has a 50-day moving average of $261.05 and a 200 day moving average of $226.28. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.98 and a quick ratio of 6.98.

Heska (NASDAQ:HSKA) last issued its earnings results on Tuesday, August 3rd. The medical research company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.13. The company had revenue of $64.93 million during the quarter, compared to analysts’ expectations of $56.82 million. Heska had a positive return on equity of 1.42% and a negative net margin of 0.59%. The firm’s quarterly revenue was up 42.0% compared to the same quarter last year. Analysts anticipate that Heska Co. will post 0.52 EPS for the current year.

In other Heska news, COO Nancy Wisnewski sold 1,000 shares of the stock in a transaction that occurred on Wednesday, August 18th. The stock was sold at an average price of $270.33, for a total value of $270,330.00. Following the completion of the sale, the chief operating officer now owns 55,499 shares in the company, valued at approximately $15,003,044.67. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Catherine Grassman sold 5,000 shares of the stock in a transaction that occurred on Friday, August 6th. The stock was sold at an average price of $260.24, for a total value of $1,301,200.00. Following the completion of the sale, the chief financial officer now owns 8,986 shares of the company’s stock, valued at approximately $2,338,516.64. The disclosure for this sale can be found here. Insiders have sold a total of 8,000 shares of company stock valued at $2,105,190 over the last 90 days. 8.60% of the stock is currently owned by company insiders.

Heska Company Profile

Heska Corp. engages in the provision of veterinary and animal health diagnostic, and specialty products. It operates through the North America and International segments. The North America segment includes the United States, Canada, and Mexico. The International segment involves Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland.

Featured Article: What economic reports are most valuable to investors?

Want to see what other hedge funds are holding HSKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heska Co. (NASDAQ:HSKA).

Institutional Ownership by Quarter for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.